Medicure Inc. filed an abbreviated new drug application to the U.S. FDA for a cardiovascular generic drug, developed as a collaboration between Medicure unit Medicure International Inc. and Apicore US LLC.

The filing was the result of a project focused on the development of an intravenous drug product for an acute cardiovascular indication.

The company and Apicore have entered into an exclusive product supply and development agreement under which Medicure holds all commercial rights.

Medicure currently owns majority interest in Apicore, with an option to acquire the remaining issued shares of Apicore until July 2017.